New Enterprise Associates
http://www.nea.com/Home/New Enterprise Associates is a venture capital firm based in Baltimore, MD. The firm has backed more than 160 companies that have gone public and invested in more than 230 companies that have been successfully merged or acquired. NEA focuses its investments in the information technology, healthcare, and energy technology industries. While NEA makes a majority of its investments in the United States, the firm invests around the world in China and India. The firm was founded in 1978.
View Older Stories View More Recent Stories
-
New Web3 Learning Platform, Proof of Learn, Offers A New Approach to Accessible, High-Quality Education Across The Globe
-
/C O R R E C T I O N -- Proof of Learn/
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
Lumos Pharma Reaches 50% Randomization Milestone in Phase 2 OraGrowtH210 Trial Evaluating Oral LUM-201 in PGHD
-
MBX Biosciences Appoints Richard B. Bartram as Chief Financial Officer
-
VIPC’s Virginia Venture Partners Investment in SCOUT Supports the First In-Space Observation Systems to Safeguard Orbital Infrastructure
-
Trevi Therapeutics (TRVI) Announces $55 Million Private Placement of Common Stock, Warrants
-
Claudia Fan Munce Joins Arteris IP Board of Directors
-
Claudia Fan Munce Joins Arteris IP Board of Directors
-
Trevi Therapeutics Announces $55 Million Private Placement Priced At-the-Market
-
Gwyneth Paltrow, Cameron Diaz-backed Evernow raises $28.5 million
-
MBX Biosciences Appoints Ora Hirsch Pescovitz, M.D., to Board of Directors
-
Runway Growth Capital Announces a Senior Secured Term Loan of $25 Million to Revelle Aesthetics
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
Lumos Pharma to Participate in the Cantor Rare Disease Symposium
-
HEAVY.AI Introduces New Capabilities that Enable Organizations to Gain Faster Access to Rapidly Growing Data Sets and Deliver Decision-Quality Information
-
Pionyr Immunotherapeutics Presents on Third Myeloid-Directed Therapeutic Program at Keystone Symposium
-
ForAllSecure Raises $21 Million to Secure the World's Software
-
Topia's Spring Release Reveals Industry-First Arrivals, Continued Expansion of Off-The-Shelf Integrations, and Enhanced Employee Experience
-
Former FDA Head Scott Gottlieb, M.D. to Headline Upcoming Artificial Intelligence in Healthcare and Diagnostics Conference
-
Regulus Therapeutics Reports Fourth Quarter and Year-End 2021 Financial Results and Recent Updates
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Lumos Pharma Reports Full Year 2021 Financial Results and Announces Plan to Perform Interim Analyses of OraGrowtH Trials
-
Top Life Science Venture Partners Join Panel At LSI 2022 Medtech Investor Summit
-
SafeBase, Inc. Raises $18 Million Series A Round to Develop Security Trust Centers for Companies
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
Lumos Pharma to Participate in Upcoming Investor Conferences
-
VIPC’s Virginia Venture Partners Invests in ClaimEdge to Help Insurance Companies Resolve Lawsuits Faster and More Cost Effectively
-
Topia Study: Remote Work Expectations Driving Resignations, Reshaping Competition for Talent
-
Cognito Therapeutics and Aetion Announce Partnership to Use Artificial Intelligence to Identify Rapidly Progressing Forms of Mild Cognitive Impairment and Alzheimer's Disease
-
Pionyr Immunotherapeutics Doses First Patient in Phase 1b Expansion Study of PY314
-
Forbes Names Strive Health One of America’s Best Startup Employers 2022
-
Eight Nephrology Practices Partner With Strive Health and SSM Health to Improve Kidney Care for St. Louis Area Medicare Patients
-
Former FDA Chief, Scott Gottlieb, to Keynote The Healthcare Innovation Congress (thINc360), May 22-26
-
OmniSci Announces Rebrand to HEAVY.AI to Mark a New Era of Advanced Analytics for Time-sensitive Decision-making at Enterprise Scale
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Lumos Pharma to Report Full Year 2021 Financial Results and Host Conference Call on March 10, 2022
-
Timescale Valuation Rockets to Over $1B with $110M Round, Marking the Explosive Rise of Time-Series Data
-
SeMI Technologies' $16M Series A Round Highlights a New Wave of AI-first Database Tech
-
VIPC’s Virginia Venture Partners Investment in RegScale Supports Growing Needs for Compliance Automation Solutions
-
Beyond Identity Raises $100 Million to Accelerate Adoption of Invisible, Un-phishable MFA for Customers and Employees
-
Beyond Identity Raises $100 Million to Accelerate Adoption of Invisible, Un-phishable MFA for Customers and Employees
-
Topia Caps Off Banner Year of Innovation, Delivering Award-Winning Solutions that Help Companies Tackle the New Dynamics of Remote and Hybrid Work
-
Form SC 13D Arcellx, Inc. Filed by: New Enterprise Associates 15, L.P.
-
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline
-
Form SC 13G Tuya Inc. Filed by: New Enterprise Associates 14, L.P.
-
Michigan Kidney Consultants and St. Clair Nephrology Team with Strive Health to Launch Innovative Kidney Care Partnership
-
Stablix Names Tony Kingsley CEO
-
hOS Secures $12.8M Seed Round Led by NEA
-
Form SC 13D/A Robinhood Markets, Inc. Filed by: New Enterprise Associates 15, L.P.

